GnRH and Endometriosis

Peptide Approaches to Endometriosis Treatment

13 min read|March 25, 2026

GnRH and Endometriosis

72%

of women on high-dose elagolix achieved clinically meaningful improvement in menstrual pain at 3 months, versus 20% on placebo.

Taylor et al., N Engl J Med, 2017

View as image

Endometriosis affects approximately 190 million women worldwide, causing chronic pelvic pain, dysmenorrhea, and infertility. For decades, the primary pharmaceutical approach involved injectable GnRH agonist peptides like leuprolide and goserelin, which suppress estrogen by desensitizing the pituitary GnRH receptor. These work, but the side effects of complete estrogen suppression (bone loss, hot flashes, vaginal dryness) limited treatment to 6-12 months. The approval of oral GnRH antagonists, beginning with elagolix in 2018, introduced dose-dependent estrogen suppression that could be calibrated to balance pain relief against hypoestrogenic side effects. This article covers the full landscape of peptide-based endometriosis therapies, from the original injectable agonists through oral antagonists to emerging peptide targets beyond the GnRH axis. For the mechanistic details of GnRH suppression, see GnRH Agonists for Endometriosis: How Suppression Treats Pain and for the specific oral antagonist comparison, see Elagolix and Relugolix: Oral GnRH Antagonists for Endometriosis.

Key Takeaways

Elagolix (200 mg twice daily) reduced dysmenorrhea in 72% of patients versus 20% on placebo at 3 months, with nonmenstrual pelvic pain improving in 55-58% versus 37% (Taylor et al., NEJM, 2017)
Relugolix combination therapy (40 mg + estradiol/norethindrone add-back) maintained pain relief for 2 full years with an acceptable bone density profile (Becker et al., 2024)
Linzagolix received European Commission marketing authorization in January 2025 for endometriosis-associated pain
Injectable GnRH agonists (leuprolide, goserelin) remain effective but cause full estrogen suppression, limiting safe use to 6-12 months without add-back therapy
CGRP signaling through RAMP1 on macrophages drives endometriosis-associated pain through nociceptor-immune crosstalk, independent of the GnRH axis (Fattori et al., 2024)
CXCR4-targeted peptide nanoparticles carrying anti-angiogenic RNAi reduced lesion size in rat endometriosis models, representing a non-hormonal peptide approach (Egorova et al., 2025)

GnRH Agonists: The Original Peptide Therapy

GnRH (gonadotropin-releasing hormone) is a 10-amino acid peptide released in pulses from the hypothalamus. It stimulates the anterior pituitary to secrete luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which drive ovarian estrogen production. Endometriosis lesions are estrogen-dependent; suppressing estrogen starves the lesions and reduces pain.

GnRH agonists (leuprolide, goserelin, nafarelin, buserelin) are modified peptides with amino acid substitutions that increase GnRH receptor binding affinity and resist enzymatic degradation. When administered continuously rather than in pulses, they initially cause a "flare" of LH and FSH release, followed by receptor desensitization and downregulation. Within 2-4 weeks, estrogen levels fall to menopausal range.

Paoletti et al. (2025) reviewed the pharmacokinetic considerations for GnRH agonists and antagonists in endometriosis, noting that depot formulations of leuprolide (monthly or 3-monthly injections) provide sustained suppression but offer no dose flexibility; once injected, the drug cannot be titrated or discontinued quickly.^[1] Bone mineral density loss of 3-6% over 6 months is a consistent finding across GnRH agonist trials. Add-back therapy with low-dose estrogen and progestin mitigates this but complicates the regimen.

For more on how kisspeptin sits upstream of GnRH in this hormonal cascade, see Kisspeptin and GnRH: How One Peptide Controls Your Reproductive Hormones.

Oral GnRH Antagonists: The Dose-Flexible Revolution

GnRH antagonists block the GnRH receptor competitively, producing immediate, dose-dependent suppression of LH and FSH without the initial flare seen with agonists. The oral formulations allow daily dose adjustment and rapid reversibility (estrogen levels recover within days of stopping the drug).

Elagolix (Orilissa)

Elagolix was the first oral GnRH antagonist approved for endometriosis (FDA, 2018). Taylor et al. (2017) published the pivotal Elaris EM-I and EM-II trials in the New England Journal of Medicine, testing two doses in nearly 1,700 premenopausal women with moderate to severe endometriosis-associated pain.^[2]

Lower dose (150 mg once daily): Achieved partial estrogen suppression. At 3 months, 46% of women had clinically meaningful improvement in dysmenorrhea versus 20% on placebo. Nonmenstrual pelvic pain responder rates were 50.4% and 49.8% in the two trials versus 36.5% on placebo.

Higher dose (200 mg twice daily): Achieved near-complete estrogen suppression. At 3 months, 72% had clinically meaningful dysmenorrhea improvement. Nonmenstrual pelvic pain responder rates were 54.5% and 57.8%.

The tradeoff was clear: higher efficacy came with more hypoestrogenic side effects. Hot flashes occurred in 24% of high-dose patients versus 6% on placebo. Bone mineral density decreased in a dose-dependent manner.

Surrey et al. (2018) published extension study data showing that elagolix maintained pain reduction through 12 months of continuous treatment, but bone mineral density loss continued to accumulate, particularly at the higher dose.^[3] Leyland et al. (2021) provided a clinical guide noting that the lower dose is preferred for long-term use because it provides meaningful pain relief while preserving more estrogen activity, reducing bone density concerns.^[4]

Relugolix Combination Therapy (Myfembree)

Relugolix takes a different approach: combining the GnRH antagonist (40 mg) with standardized add-back therapy (1 mg estradiol + 0.5 mg norethindrone acetate) in a single daily tablet. The add-back is built into the product rather than prescribed separately.

Giudice et al. (2022) published the SPIRIT 1 and SPIRIT 2 pivotal trial results, showing that relugolix combination therapy significantly reduced dysmenorrhea and nonmenstrual pelvic pain compared to placebo over 24 weeks.^[5]

Becker et al. (2024) published two-year efficacy and safety data demonstrating that pain relief was sustained through 24 months of continuous treatment. Bone mineral density changes were minimal with the built-in add-back therapy, supporting long-term use.^[6] This addresses the major limitation of both injectable GnRH agonists and high-dose elagolix: the inability to treat safely beyond 6-12 months.

Linzagolix (Yselty)

Linzagolix received European Commission marketing authorization in January 2025 for endometriosis-associated pain. It is available in multiple dose options (75 mg and 200 mg), with the lower dose intended for use without add-back and the higher dose with add-back therapy. This dose flexibility allows clinicians to calibrate the degree of estrogen suppression to the individual patient's pain severity and tolerance for side effects.

Neuropeptides in Endometriosis Pain

The GnRH axis drugs address endometriosis by suppressing the hormonal environment that feeds lesion growth. But endometriosis pain involves a separate set of peptide mediators that drive neuroinflammation and visceral hypersensitivity.

Substance P and CGRP

Yan et al. (2019) demonstrated that the neuropeptides substance P and calcitonin gene-related peptide (CGRP) accelerate both the development and fibrogenesis of endometriosis in animal models.^[7] These neuropeptides are released by sensory nerve fibers that innervate endometriotic lesions. Substance P promotes neurogenic inflammation and mast cell degranulation, while CGRP causes vasodilation and immune cell recruitment. Together, they create a pain-amplifying feedback loop where nerve growth into lesions drives inflammation, which drives more nerve growth.

Fattori et al. (2024) identified CGRP/RAMP1 signaling as a direct mechanism of endometriosis pain, showing that nociceptor-to-macrophage communication through this pathway drives pain behavior independent of lesion size or hormonal status.^[8] This finding is significant because it explains why some women continue to experience pain even after adequate hormonal suppression: the neuropeptide-driven pain circuitry can become self-sustaining. For more on how CGRP mediates pain, see CGRP and Migraines: The Peptide Discovery That Revolutionized Headache Treatment and Substance P and Pain: The Neuropeptide That Amplifies Your Suffering.

Nociceptin/Orphanin FQ

Guan et al. (2023) characterized the expression of the nociceptin/orphanin FQ opioid peptide receptor (NOP) in endometriosis-associated nerve fibers, finding altered NOP expression patterns that may contribute to the aberrant pain signaling seen in the disease.^[9] This opioid-like peptide system operates outside the classical mu/delta/kappa opioid receptor framework and represents a potential non-hormonal therapeutic target.

Emerging Non-Hormonal Peptide Approaches

CXCR4-Targeted Peptide Nanoparticles

Egorova et al. (2025) tested CXCR4-targeted peptide nanoparticles carrying anti-angiogenic RNAi (targeting VEGFA) in a rat endometriosis model.^[10] The CXCR4-targeting peptide directed the nanoparticles specifically to endometriotic lesions, which overexpress the CXCR4 receptor. The anti-angiogenic payload reduced new blood vessel formation feeding the lesions, resulting in decreased lesion size. This represents a conceptually different approach: using peptides as targeting vehicles to deliver anti-endometriosis therapies directly to lesions rather than suppressing the systemic hormonal environment.

GHRH Antagonists

Koster et al. (2017) demonstrated that an antagonistic analog of growth hormone-releasing hormone (GHRH) reduced endometriotic lesion size in a mouse model.^[11] The mechanism is distinct from GnRH: GHRH antagonists appear to directly inhibit cell proliferation in endometriotic tissue through GHRH receptors expressed on the lesions themselves, independent of pituitary hormone suppression. This finding has not been translated to human trials.

Comparing Approaches: Agonists vs. Antagonists vs. Emerging Targets

Approach	Mechanism	Route	Onset	Reversibility	Key Limitation
GnRH agonists (leuprolide)	Receptor desensitization	Injection (depot)	2-4 weeks (after flare)	Weeks-months	Bone loss, no dose flexibility
Elagolix 150 mg	GnRH receptor blockade	Oral, daily	Days	Days	Moderate efficacy at lower dose
Elagolix 200 mg BID	GnRH receptor blockade	Oral, daily	Days	Days	Significant bone loss
Relugolix combo	GnRH blockade + add-back	Oral, daily	Days	Days	Add-back may reduce maximal efficacy
Linzagolix	GnRH receptor blockade	Oral, daily	Days	Days	Limited long-term data
CGRP/RAMP1 targeting	Pain pathway interruption	Experimental	Unknown	Unknown	Preclinical only
CXCR4-peptide nanoparticles	Lesion-targeted anti-angiogenesis	Experimental	Unknown	Unknown	Animal model only

The shift from injectable GnRH agonists to oral antagonists with built-in add-back represents the most significant practical advance. Women can start and stop treatment immediately, titrate doses based on response, and maintain treatment for years rather than months. The emerging neuropeptide targets (CGRP, substance P, nociceptin) and peptide-targeted delivery systems address different aspects of the disease: the pain circuitry and the lesions themselves, rather than only the hormonal environment.

What the Current Landscape Misses

None of the approved peptide-based treatments cure endometriosis. GnRH suppression manages symptoms while treatment continues, but pain typically returns within months of stopping therapy. Bone density concerns limit the duration of high-dose regimens. The neuropeptide-driven pain pathways identified by Fattori et al. (2024) and Yan et al. (2019) suggest that some endometriosis pain is maintained independently of estrogen, which explains treatment failures with hormonal therapy alone.

The most promising research direction combines hormonal suppression with targeted approaches that address the inflammatory, neurogenic, and angiogenic components of the disease. Peptide-targeted nanoparticles that deliver anti-angiogenic or anti-inflammatory payloads directly to lesions could complement GnRH antagonist therapy. Anti-CGRP therapies, already proven effective for migraine, represent a near-term opportunity for repurposing in endometriosis pain. See CGRP Antagonists Explained: How Anti-CGRP Drugs Stop Migraines for how these drugs work.

The Bottom Line

Peptide-based endometriosis treatment has evolved from injectable GnRH agonists with severe side effects to oral GnRH antagonists with dose-dependent estrogen suppression and built-in add-back therapy. Elagolix, relugolix, and linzagolix offer meaningful pain relief for dysmenorrhea and nonmenstrual pelvic pain. Beyond the GnRH axis, neuropeptides like CGRP and substance P drive endometriosis pain through neuroinflammatory mechanisms independent of hormonal status, and targeted peptide nanoparticles are being tested for lesion-specific drug delivery. No peptide therapy cures endometriosis, but the combination of hormonal management with emerging neuropeptide-targeted and angiogenesis-targeted approaches may address the disease more comprehensively than any single pathway.

Frequently Asked Questions

Three categories of peptide-related drugs treat endometriosis. Injectable GnRH agonists (leuprolide, goserelin) are synthetic peptides that desensitize pituitary GnRH receptors to suppress estrogen. Oral GnRH antagonists (elagolix, relugolix, linzagolix) are small molecules that competitively block GnRH receptors for dose-dependent estrogen suppression. Elagolix was FDA-approved in 2018, relugolix combination therapy in 2022, and linzagolix received European authorization in January 2025. All work by reducing the estrogen that feeds endometriotic lesions.

In two phase 3 trials published in the New England Journal of Medicine (Taylor et al., 2017), elagolix at 200 mg twice daily reduced dysmenorrhea in 72% of women at 3 months versus 20% on placebo. The lower 150 mg once-daily dose achieved improvement in 46%. For nonmenstrual pelvic pain, response rates were 50-58% for elagolix versus 37% for placebo. The higher dose produces more pain relief but also more hot flashes (24% versus 6%) and greater bone density loss.

GnRH agonists (leuprolide, goserelin) initially stimulate, then desensitize the pituitary, causing a hormone "flare" before estrogen drops to menopausal levels over 2-4 weeks. They are injected as depot formulations and cannot be dose-adjusted. GnRH antagonists (elagolix, relugolix, linzagolix) competitively block the receptor, producing immediate, dose-dependent suppression without a flare. They are taken orally and can be stopped with estrogen recovering within days. Antagonists offer more flexibility and faster onset.

Becker et al. (2024) published two-year data showing that relugolix combination therapy (40 mg relugolix + estradiol + norethindrone acetate) maintained pain relief through 24 continuous months. Bone mineral density changes were minimal with the built-in add-back therapy. This is a meaningful improvement over injectable GnRH agonists and high-dose elagolix, which are typically limited to 6-12 months due to bone density concerns. Longer-term data beyond 2 years is still being collected.

Non-hormonal peptide approaches are in early research stages. CGRP/RAMP1 signaling was identified as a direct pain mechanism in endometriosis (Fattori et al., 2024), suggesting that anti-CGRP drugs already approved for migraine could be repurposed. CXCR4-targeted peptide nanoparticles carrying anti-angiogenic RNA reduced lesion size in rats (Egorova et al., 2025). GHRH antagonist peptides also reduced lesions in mice by directly inhibiting cell proliferation. None have reached human clinical trials for endometriosis specifically.

Fattori et al. (2024) showed that CGRP released by sensory nerve fibers communicates with macrophages through RAMP1 receptors, driving pain independently of estrogen levels or lesion size. Yan et al. (2019) found that substance P and CGRP promote nerve fiber growth into lesions, creating a self-sustaining neuroinflammatory circuit. Even when hormonal suppression reduces estrogen-dependent lesion activity, these neuropeptide-driven pain pathways can continue operating, explaining persistent symptoms in some patients.